SLS

SELLAS LIFE SCIE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.700
+0.150
+5.88%
After Hours: 2.770 +0.07 +2.59% 17:34 09/18 EDT
OPEN
2.460
PREV CLOSE
2.550
HIGH
2.910
LOW
2.460
VOLUME
444.03K
TURNOVER
--
52 WEEK HIGH
10.89
52 WEEK LOW
1.455
MARKET CAP
25.55M
P/E (TTM)
-0.4874
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average SLS stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SLS
SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sellas Life Sciences Group Inc stock information, including NASDAQ:SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.